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Abstract
Background: a-thalassemia results from decreased production of a-globin chains that make up part of hemoglobin
tetramers (Hb; a2b2) and affects up to 50% of individuals in some regions of sub-Saharan Africa. Heterozygous (2a/aa) and
homozygous (2a/2a) genotypes are associated with reduced risk of severe Plasmodium falciparum malaria, but the
mechanism of this protection remains obscure. We hypothesized that a-thalassemia impairs the adherence of parasitized
red blood cells (RBCs) to microvascular endothelial cells (MVECs) and monocytes – two interactions that are centrally
involved in the pathogenesis of severe disease.
Methods and Findings: We obtained P. falciparum isolates directly from Malian children with malaria and used them to
infect aa/aa (normal), 2a/aa and 2a/2a RBCs. We also used laboratory-adapted P. falciparum clones to infect 2/2a RBCs
obtained from patients with HbH disease. Following a single cycle of parasite invasion and maturation to the trophozoite
stage, we tested the ability of parasitized RBCs to bind MVECs and monocytes. Compared to parasitized aa/aa RBCs, we
found that parasitized 2a/aa, 2a/2a and 2/2a RBCs showed, respectively, 22%, 43% and 63% reductions in binding to
MVECs and 13%, 33% and 63% reductions in binding to monocytes. a-thalassemia was associated with abnormal display of
P. falciparum erythrocyte membrane protein 1 (PfEMP1), the parasite’s main cytoadherence ligand and virulence factor, on
the surface of parasitized RBCs.
Conclusions: Parasitized a-thalassemic RBCs show PfEMP1 display abnormalities that are reminiscent of those on the
surface of parasitized sickle HbS and HbC RBCs. Our data suggest a model of malaria protection in which a-thalassemia
ameliorates the pro-inflammatory effects of cytoadherence. Our findings also raise the possibility that other unstable
hemoglobins such as HbE and unpaired a-globin chains (in the case of b-thalassemia) protect against life-threatening
malaria by a similar mechanism.
Citation: Krause MA, Diakite SAS, Lopera-Mesa TM, Amaratunga C, Arie T, et al. (2012) a-Thalassemia Impairs the Cytoadherence of Plasmodium falciparum-
Infected Erythrocytes. PLoS ONE 7(5): e37214. doi:10.1371/journal.pone.0037214
Editor: Tobias Spielmann, Bernhard Nocht Institute for Tropical Medicine, Germany
Received November 21, 2011; Accepted April 16, 2012; Published May 18, 2012
This is an open-access article, free of all copyright, and may be freely reproduced, distributed, transmitted, modified, built upon, or otherwise used by anyone for
any lawful purpose. The work is made available under the Creative Commons CC0 public domain dedication.
Funding: This research was supported by the Intramural Research Program of the National Institute of Allergy and Infectious Diseases, National Institutes of
Health. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: rfairhurst@niaid.nih.gov
Introduction
a-thalassemia is an inherited disorder of hemoglobin (Hb)
synthesis, in which reduced production of a-globin chains leads
to decreased amounts of normal a2b2 tetramers and increased
amounts of unpaired b-globin chains. In sub-Saharan Africa, a-
thalassemia states are produced by a 3.7-kb deletion that leaves
one functional copy of duplicated a-globin genes. Heterozygotes
(2a/aa) have an essentially normal phenotype while homozy-
gotes (2a/2a) have mild microcytic anemia. HbH disease is a
chronic hemolytic disorder that may produce severe anemia
requiring periodic blood transfusions. While the prevalence of a-
thalassemia can exceed 50% in some malaria-endemic areas of
sub-Saharan Africa, HbH disease (2/2a) is extremely rare
because the mutant cis allele (2/) is very uncommon.
One study associated a-thalassemia with reduced risk of severe
Plasmodium falciparum malaria in Papua New Guinea [1], but only
recently have epidemiological studies confirmed this finding in
sub-Saharan Africa. Case-control and cohort studies have shown
that heterozygous and homozygous a-thalassemia variously
protect against severe malaria syndromes, including cerebral
malaria (CM; coma with or without convulsions), severe malarial
anemia (SMA; Hb level #50 g/l), and deep acidotic breathing
[2,3,4,5]. While these observations provide strong evidence that a-
thalassemia prevents the progression from uncomplicated to severe
malaria, the mechanism of this protection has not been
established.
PLoS ONE | www.plosone.org 1 May 2012 | Volume 7 | Issue 5 | e37214In considering candidate mechanisms of protection by a-
thalassemia, we reasoned that they should be consistent with a
well-established epidemiological observation reported from nu-
merous African settings. Specifically, a-thalassemia is not associ-
ated with reduced parasite prevalence [5,6,7] or densities in vivo as
determined by examining blood smears from children with
asymptomatic parasitemia [2,8], uncomplicated malaria
[2,3,4,5,6,7,9,10,11,12], or severe malaria [2,13]. As noted by
other investigators [3,5,14], these observations indicate that a-
thalassemia does not protect against severe malaria by mecha-
nisms that impair the ability of parasites to invade or develop
within RBCs [15,16], or promote the removal of parasitized RBCs
from the bloodstream by increased neoantigen expression [15,17]
or increased antibody binding [18]. Indeed, we have observed
extremely high parasite burdens (up to 200,000/ml) in some 2a/
aa and 2a/2a children with malaria (unpublished data).
A central question thus emerges from these considerations: how
can marginal decreases in a-globin synthesis enable children to
develop high parasite densities and symptoms of uncomplicated
malaria and yet not develop severe complications of the disease?
To explore this question, we hypothesized that a-thalassemia
impairs the adherence of parasitized RBCs to microvascular
endothelial cells (MVECs) and monocytes. These cell-cell interac-
tions are mediated by P. falciparum erythrocyte membrane protein
1 (PfEMP1), a family of clonally-expressed, antigenically-variant
proteins [23,24,25]. P. falciparum parasites export PfEMP1 proteins
and concentrate them in knob-like protrusions on the surface of
their host RBCs. This host cell modification enables a large mass
of parasitized RBCs to sequester in venous microvessels [26] and
avoid clearance from the bloodstream by the spleen. However, the
adherence of parasitized RBCs to MVECs and monocytes also
contributes to the development of life-threatening malaria by
causing systemic microvascular inflammation [27,28,29,30].
Using naturally-circulating P. falciparum isolates and freshly-
drawn RBCs from our study site in rural Mali, where
approximately 40% of children are a-thalassemic, we show that
a-thalassemia impairs the cytoadherence of parasitized RBCs
and is associated with abnormal PfEMP1 display.
Methods
Red Blood Cells
All blood samples were obtained from healthy Malian children
who were confirmed to be aparasitemic by examination of thick
blood smears. Blood samples from two patients with HbH disease
were obtained in the United States. Written, informed consent was
obtained from all blood donors or their parents. Blood collection
was approved by the Institutional Review Boards of the National
Institute of Allergy and Infectious Diseases, the University of
Bamako, and the Johns Hopkins School of Medicine. Whole blood
samples were drawn into VacutainersH (Becton-Dickinson, Frank-
lin Lakes, NJ) containing acid-citrate-dextrose (ACD) anticoagu-
lant. After removing buffy coat leukocytes, RBCs were washed
three times with RPMI-1640 (Invitrogen, Carlsbad, CA) and
stored at 50% hematocrit at 4uC prior to use (within 4–36 h of
blood draw). In some flow cytometry experiments, whole blood
samples were stored in ACD VacutainersH on ice during a 36-hour
transport from Mali to the United States and then used within 4–
24 h of arrival. Hemoglobin types were determined by HPLC (D-
10 Instrument, Bio-Rad, Hercules, CA). The presence of the
G6PD*A2 allele was determined as described [19]. The presence
of the 3.7-kb deletional determinant of a-thalassemia was
determined as described [20]. In all experiments, normal and a-
thalassemic RBCs were obtained simultaneously and processed in
parallel. Normal and a-thalassemic RBC donors from Mali had
normal HbA and did not carry the G6PD*A2 allele.
Parasite Culture
P. falciparum clones (3D7, FCR-3, A4tres and FVO) were
cultured in O+ RBCs at 5% hematocrit in complete medium (CM;
RPMI-1640 supplemented with 25 mg/ml HEPES, 2 mg/mL
sodium bicarbonate, 50 mg/ml gentamicin, and 0.5% Albumax II
(Gibco-BRL, Grand Island, NY) in 0.2 mm-vented, 75-cm
2 flasks
(Corning Inc., Corning, NY). Knobby parasite lines were
maintained by periodic gelatin flotation [21]. Cultures were
maintained at 37uC in a humidified atmosphere of 5% CO2 and
media was changed every 8–12 h. Naturally-circulating P.
falciparum isolates (ring stage) were obtained directly from Malian
children with malaria and cultured for 12–24 hours to the
trophozoite stage, as above. Trophozoite-infected RBCs contain-
ing paramagnetic hemozoin were enriched to .95% purity by
magnetic separation (Miltenyi Biotec, Auburn, CA), inoculated
into normal and a-thalassemic RBC samples, and cultured at 1–
2% hematocrit as above. In all experiments, parasitized RBCs
were assayed after one cycle of invasion and development to the
trophozoite stage (,36 h).
Endothelial Cell Adherence Assay
Endothelial cell adherence assays were conducted in Mali,
except those using HbH RBCs obtained in the United States.
Human adult dermal microvascular endothelial cells (MVECs;
Lonza, Walkersville, MD) were maintained in the manufacturer’s
EGM2-MV medium and grown on LabTek CC-2 coated 8-well
chamber slides (Nalge Nunc International, Rochester, NY) to
,50% confluency at 37uC in a humidified atmosphere of 5%
CO2. Trophozoite-infected RBCs were adjusted to 5–20%
parasitemia and 1% hematocrit by the addition of noninfected
RBCs in binding media (BM; RPMI-1640, 0.5% BSA, pH 6.7).
Adherent MVECs were washed with BM and then incubated with
150 ml of the parasitized RBC suspension for 1 h at 37uC with
constant horizontal agitation (100 rpm). After parasite suspensions
were removed from each well, slides were washed by dipping twice
in BM at 37uC, fixed in 2% glutaraldehyde at ambient
temperature for 2 h, and stained in 1 or 2.5% Giemsa for 30–
60 min. In each experiment, the number of parasitized RBCs
bound to ,700 MVECs was counted from duplicate wells. For
each slide, the number of parasitized a-thalassemic RBCs per
MVEC was normalized to counts from parasitized normal RBCs.
Monocyte Adherence Assay
Monocyte adherence assays were conducted in Mali, except
those using HbH RBCs obtained in the United States. CD14+
monocytes (Lonza) were plated onto CC2 Lab-Tek chamber
slides (Nalge Nunc International) at 4610
5 cells per well and
cultured for 48 h in RPMI 1640 containing 25 mM HEPES,
50 mg/ml gentamicin, and 10% fetal bovine serum at 37uCi na n
atmosphere of 5% CO2. Normal and a-thalassemic RBCs
infected with P. falciparum trophozoites (3D7, A4tres, FCR-3,
naturally-circulating isolates) were purified by magnetic separa-
tion, adjusted to 3–15% parasitemia and 1% hematocrit as
previously described. Adherent monocytes were washed with
binding media and incubated with 150 ml of the parasitized RBC
suspension for 1 h at 37uC with gentle horizontal rotation. The
parasite suspension was removed from each well and the slides
were gently washed by dipping four times in binding media.
Slides were dried and stained using Hema 3 (Fischer Scientific).
Adherence was measured by counting the number of infected
RBCs bound to a minimum of 700 monocytes from duplicate
a-Thalassemia and Malaria Protection
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RBCs per monocyte was normalized to the counts from
parasitized normal RBCs.
Flow Cytometry
Flow cytometry was conducted in the United States using a-
thalassemic RBCs obtained in Mali and HbH RBCs obtained in
the United States. Rat or rabbit polyclonal antisera raised against
PfEMP-1 variants expressed by the P. falciparum clones FVO and
A4tres were kindly provided by Morris Makobongo and Dror
Baruch (NIAID). Rabbit polyclonal antisera specific for a
recombinant PfEMP1 variant subdomain (VAR2CSA, DBL3X)
was kindly provided by Kavita Singh (NIAID). Samples of
trophozoite-infected RBCs (1.5610
6 cells; 1% parasitemia) were
stained with various dilutions of antiserum in FACS staining buffer
(FSB; PBS, 2% FBS, 0.1% sodium azide) for 45 min at ambient
temperature and washed twice with FSB. Samples were then
incubated with Alexa 488-conjugated anti-rat or anti-rabbit IgG
(Molecular Probes, Inc., Eugene, OR) and ethidium bromide
(2 mg/ml) at ambient temperature for 30 min and washed twice
with FSB. A FACSort instrument (Becton-Dickinson, San Jose,
CA) and FlowJo software (Tree Star, Inc., Ashland, OR) were used
to acquire and analyze 250,000 to 500,000 events from each
sample.
Atomic Force Microscopy
Parasitized a-thalassemic RBCs were obtained directly from
Malian children with malaria, cultured to the trophozoite stage,
and prepared for atomic force microscopy (AFM) imaging as
described [22]. We also inoculated HbH RBCs with P. falciparum
clone FCR-3 and cultured them through one cycle of invasion and
development to the trophozoite stage (,36 h). A Bioscope AFM
(Veeco Instruments, Santa Barbara, CA) on a wide-field Axiovert
200 fluorescence microscope (Carl Zeiss, Inc., Thornwood, NY)
was optimized to image the surface topography of RBCs and to
identify the parasite stage within an individual AFM-imaged RBC.
The X and Y piezoelectric scanners of the Bioscope AFM were
disconnected. A custom built closed-loop XY scanner stage
(nPoint, Inc., Madison, WI) was used to minimize scanning
artifacts and thermal drift of the scanner for improved image
accuracy. AFM was performed in tapping mode in air using
Nanosensors pointprobe tips (Nanosensors, Switzerland) with a
cantilever resonant frequency of 327–397 kHz. Topographic and
error signal (amplitude) images were collected simultaneously.
Parasites were stained with YOYO-1 fluorescent nucleic acid
staining reagent (Molecular Probes, Inc.). Bright field and
fluorescent images were collected with a chilled CCD video
camera (Model C5985, Hamamatsu Photonic Systems, Bridge-
water, NJ). Image-Pro Plus version 5.0 software (Media Cyber-
netics, Silver Spring, MD) was used to merge these images to allow
the approximate identification of the parasite stage.
Statistical Analysis
In assays of cytoadherence and PfEMP1 expression, results from
parasitized a-thalassemic RBCs were normalized to results from
parasitized normal RBCs tested in parallel. 2-tailed P values were
calculated by one-sample t test of the mean using GraphPad
software version 5.01 (Graphpad Software, La Jolla, CA).
Results
Because cytoadherence is centrally involved in the pathogenesis
of severe malaria, we tested P. falciparum-infected normal and a-
thalassemic RBCs for their adherence to MVECs. In these and
other cytoadherence comparisons, we used naturally-circulating
P. falciparum isolates obtained directly from Malian children with
malaria, and freshly-drawn nonparasitized RBCs from healthy
Malian children. In experiments using 2/2a RBCs, we used
laboratory-adapted P. falciparum clones, and freshly-drawn RBCs
from two patients with HbH disease. Relative to parasitized aa/
aa RBCs, parasitized 2a/aa and 2a/2a RBCs showed 22%
and 43% reductions in adherence to MVECs, respectively (mean
6 SEM; 78%66.6%, P=0.007, N=12 for 2a/aa; 57%613.0%,
P=0.03, N=5 for 2a/2a)( Fig. 1a). Although the 2/2a
phenotype is not present in sub-Saharan Africa, we chose to use
2/2a RBCs to test the effects of further reductions in a-globin
expression on cytoadherence. Parasitized 2/2a RBCs showed an
89% reduction in adherence to MVECs (11%61.8%, P,0.0001,
N=4)(Fig. 1a).
P. falciparum infection is associated with elevated levels of TNF
and other monocyte-derived cytokines that cause fever and other
symptoms of malaria. Excessive levels of these cytokines correlate
with the development of severe malaria syndromes [31]; for
example, TNF causes dyserythropoiesis that contributes to the
development of severe malarial anemia. The interaction between
PfEMP1 on parasitized RBCs and CD36 on monocytes leads to
monocyte activation and cytokine production in vitro [32,33]. To
measure the effects of a-thalassemia on this interaction, we tested
the adherence of parasitized RBCs to monocytes. Relative to
parasitized aa/aa RBCs, parasitized 2a/aa, 2a/2a and 2/2a
RBCs showed 13%, 33% and 63% reductions in adherence to
monocytes, respectively (mean 6 SEM; 87%64.0%, P=0.003,
N=21 for 2a/aa; 67%69.6%, P=0.07, N=3 for 2a/2a;
37%65.8%, P=0.002, N=4 for 2/2a)( Fig. 1b).
Reduced expression of PfEMP1 on the surface of parasitized
RBCs containing the malaria-protective HbC or HbS variants is
associated with reductions in cytoadherence. Using specific
antisera in a flow cytometric assay, we found that parasitized –
a/aa and 2/2a BCs showed 18% and 43% reductions in surface
PfEMP1 levels, respectively, relative to parasitized aa/aa RBCs
(mean 6 SEM; 82%63.0%, P=0.0002, N=10 for 2a/aa;
57%64.7%, P=0.0003, N=6 for 2/2a)( Fig. 1c). We were
unable to quantify PfEMP1 levels on the surface of parasitized
2a/2a RBCs. This is because the homozygous a-thalassemic
children in our cohort had confounding polymorphisms such as
HbC, HbS and G6PD deficiency, were parasitized at the time of
screening, or refused to donate a blood sample.
On the surface of parasitized RBCs, PfEMP1 proteins are
concentrated on knob-like protrusions that make contact with host
cells [32,34,35]. Alterations in knob assembly can therefore affect
the amount and distribution of PfEMP1 [34,36]. To determine
whether reduced surface levels of PfEMP1 are associated with
aberrant knob assembly on parasitized a-thalassemic RBCs, we
examined the surface of these cells. Atomic force micrographs of
naturally-parasitized 2a/aa and 2a/2a RBCs (cultured ex vivo
from ring forms to mature trophozoites) showed populations
expressing fine, regularly distributed knobs (Fig. 2a,b) character-
istic of parasitized normal RBCs as well as cell populations
expressing large, widely separated knobs (Fig. 2d,e) reminiscent
of parasitized HbC and HbS RBCs [22,37]. Knobs on the surface
of trophozoite-infected 2/2a RBCs were found to be variously
abnormal in size and distribution (Fig. 2c) and in some cases
essentially absent (Fig. 2f).
Discussion
a-thalassemia protects against different clinical forms of severe
malaria, especially SMA but also CM and deep acidotic breathing
a-Thalassemia and Malaria Protection
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which a-thalassemia protects against these severe malaria
syndromes has remained obscure, although it does not seem to
affect parasite density in vivo. Microcytosis has recently been
implicated as a mechanism of protection against SMA by
homozygous, but not heterozygous, a-thalassemia in Papua New
Guinea [14]. According to this model, increased RBC counts
protect homozygotes against SMA by reducing the amount of Hb
loss at any given parasite density. While microcytosis might
prevent SMA, as defined as Hb concentration #50 g/l [14], the
role of a-thalassemia homozygosity in protection against death
from SMA is less clear. This is because SMA can be associated
with very low fatality rates (,1%) [38] unless it is complicated by
other signs of severe malaria, including coma and deep acidotic
breathing [4,38].
To explore how heterozygous and homozygous forms of a-
thalassemia protect against CM and complicated SMA, we
hypothesized that these traits weaken the adherence of parasitized
RBCs to host cells within microvessels – a pro-inflammatory
process that is essential in the pathogenesis of severe disease
syndromes. We found that progressive reductions in a-globin
production produce commensurate reductions in the adherence of
parasitized RBCs to MVECs and monocytes. Decreased levels and
abnormal distribution of PfEMP1 on the surface of parasitized a-
thalassemic RBCs correlate with these findings. Based on these
data, we propose the following model to explain how a-
thalassemia protects against severe malaria syndromes without
affecting parasite densities in vivo.
P. falciparum merozoites readily invade a-thalassemic RBCs and
develop into viable trophozoites expressing PfEMP1. The amount
and distribution of PfEMP1 is sufficiently normal to mediate
effective sequestration of trophozoite-infected RBCs. This normal
cycle of invasion, development, and sequestration enables parasites
to avoid clearance from the bloodstream by the spleen and to
multiply to densities that are equivalent to those observed in non-
thalassemic children with malaria. The avidity of parasitized
RBCs for MVECs and monocytes is sufficiently weakened by a-
thalassemia, however, so that these host cell populations are not
maximally activated. The resulting levels of inflammation produce
symptoms of uncomplicated malaria, but are not high enough to
cause severe disease and death. This model of protection is
consistent with recent data showing that the degree of endothelial
cell activation correlates with avidity of cytoadherence [39,40]. It
is also consistent with the finding that parasitized a-thalassemic
RBCs show impaired adherence to human umbilical vein
endothelial cells and rosetting [41,42] (the binding of a parasitized
RBC to several other noninfected RBCs), a different cytoadher-
ence interaction also implicated in the development of severe
disease.
Our model suggests that a-thalassemia heterozygous and
homozygous states confer protection against CM and complicated
SMA by impairing PfEMP1-mediated activation of host cells. By
impairing endothelial cell activation, for example, a-thalassemia
Figure 1. Relative cytoadherence and surface PfEMP1 levels of
parasitized RBCs. a, Adherence of parasitized RBCs to MVECs. The
numbers of parasitized 2a/aa (HE), 2a/2a (HO) and 2/2a (HH) RBCs
adhering to MVECs were normalized to those of parasitized aa/aa RBCs
tested in parallel. The mean (6 SEM) number of parasitized aa/aa RBCs
per 100 MVECs was 260640, N=19. Results were obtained from 19
naturally-circulating parasite isolates and 2 laboratory-adapted parasite
clones (A4tres and FCR-3), multiple blood donors (5 aa/aa,2 2a/aa,2
2a/2a and 22/2a), and 4 MVEC donors (not all combinations tested).
This resulted in 2a/aa, 2a/2a and 2/2a samples being compared to
aa/aa samples 12, 5 and 4 times. b, Adherence of parasitized RBCs to
monocytes. The numbers of parasitized 2a/aa, 2a/2a and 2/2a RBCs
adhering to monocytes were normalized to those of aa/aa RBCs tested
in parallel. The mean (6 SEM) number of parasitized aa/aa RBCs per
100 monocytes was 136610, N=12. Results were obtained from 3
naturally-circulating parasite isolates and 3 laboratory-adapted parasite
clones (3D7, A4tres and FCR-3), multiple blood donors (5 aa/aa,32a/
aa,22a/2a and 22/2a) and 4 monocyte donors (not all
combinations tested). This resulted in 2a/aa, 2a/2a and 2/2a
samples being compared to aa/aa samples 20, 3 and 4 times. The aa/
aa and 2a/aa RBCs were different from those used in endothelial cell
adherence assays. c, PfEMP1 expression levels (median fluorescence
intensities, MFI) on the surface of parasitized RBCs. The mean (6 SEM)
MFI of parasitized aa/aa RBCs was 5566153, N=6. Results were
obtained from 2 laboratory-adapted parasite clones (A4tres, FVO and
FCR3
CSA), multiple blood donors (4 aa/aa,62a/aa and 22/2a), and
various concentrations of 2 antisera (not all combinations tested). This
resulted in 2a/aa, and 2/2a samples being compared to aa/aa
samples 10 and 6 times. The aa/aa and 2a/aa RBCs were different from
those used in endothelial cell and monocyte adherence assays.
doi:10.1371/journal.pone.0037214.g001
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contributes to CM. By impairing monocyte activation, a-
thalassemia could produce lower levels of cytokines and other
inflammatory mediators that suppress erythropoiesis [43]. Some
evidence for this possibility was recently provided by Veenemans
et al. who showed that in Tanzanian and Kenyan children, a-
thalassemia limits the decline in Hb levels associated with episodes
of symptomless parasitemia – particularly those accompanied by
inflammation [8]. The lower mean corpuscular Hb concentrations
associated with a-thalassemia may contribute to this protective
mechanism by decreasing the amount of free Hb released upon
the rupture of each schizont-infected RBC. This mechanism
would have the effect of lessening the severity of free Hb-induced
endothelial cell dysfunction, as proposed by May et al. [4].
Our model also provides a plausible explanation for how
heterozygous a-thalassemia confers less protection against severe
disease than do HbS and HbC. Indeed, large numbers of a-
thalassemic children do develop severe disease despite their abnormal
RBC phenotype. Multiple studies have reported significant
numbers of a-thalassemic children who develop life-threatening
manifestations of disease [(e.g., 31% (94/301) of Ghanaian
children in [2]; 60% (391/655) of Kenyan children in [3]; and
51% (70/137) of Kenyan children in [13])]. Relatively mild
reductions in surface levels of particular PfEMP1 variants may not
suffice to significantly impair the avidity of parasitized RBCs for
host cells, resulting in relatively significant proportions of children
with severe disease carrying the heterozygous a-thalassemia
phenotype. A major limitation of our study is that it used 2a/
2a RBCs from relatively few donors. While data from 2a/2a
(and HbH) RBC samples were useful to explore the effect of a-
thalassemia dose on PfEMP1 display, additional laboratory and
epidemiological studies are needed to determine the relative
contribution of impaired cytoadherence to the malaria-protective
effects of homozygous a-thalassemia.
Parasitized a-thalassemic RBCs show PfEMP1 display abnor-
malities that are reminiscent of those on the surface of parasitized
HbS and HbC RBCs. Shared characteristics between HbS, HbC,
and a-thalassemic RBCs suggest possible mechanisms by which
these diverse hemoglobinopathies impair the ability of P. falciparum
parasites to remodel their host RBC membrane. HbS, HbC, and
unpaired b-globin chains (in the case of a-thalassemia) undergo
accelerated degradation to hemichromes [44,45]. These hemi-
chromes bind the inner leaflet of the RBC membrane where they
promote the heme iron-mediated oxidation of membrane proteins
and lipids [46,47] – a process that consumes antioxidants as well.
Since parasites induce hemichrome formation as they mature from
Figure 2. Distribution and morphology of knobs on the surface of parasitized RBCs. Atomic force micrographs (AFMs) of parasitized 2a/
aa (HE) (a,d) and 2a/2a (HO) (b,e) RBCs obtained from naturally-parasitized Malian children with malaria and 2/2a (HH) (c,f) RBCs infected with a
laboratory-adapted P. falciparum clone showing normal (a,b) or abnormal (c–f) knob distributions and morphologies. AFM images are representative
of 32, 10 and 18 images of parasites in 2a/aa, 2/2aa and 2/2a RBCs. Inlays show YOYO-1-stained parasites that correspond to those imaged by
AFM. Comparison AFMs of parasitized HbA, HbC and HbS RBCs have been reported previously [22,37].
doi:10.1371/journal.pone.0037214.g002
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produced by parasites in HbS, HbC, and a-thalassemic RBCs
would be greater than in normal RBCs [49]. Excessive hemi-
chrome-induced damage to the parasitized RBC membrane could
interfere with the trafficking and knob incorporation of PfEMP1.
Finally, our data suggest that a-thalassemia protects against
severe P. falciparum malaria by the same mechanism as HbS and
HbC: ameliorating the pro-inflammatory effects of cytoadherence.
This model also raises the possibility that other unstable
hemoglobins such as HbE and unpaired a globin chains (in the
case of b-thalassemia) protect against severe malaria by a similar
mechanism. While appropriate case-control and cohort studies
have not yet been conducted to determine whether HbE or b-
thalassemia confer protection against fatal malaria syndromes,
neither hemoglobinopathy has been associated with reduced
parasite prevalence or densities in vivo [50,51,52]. We speculate
that diverse hemoglobinopathies have been naturally selected
worldwide for the common phenotype of abnormal PfEMP1
display. If true, these findings would suggest that PfEMP1-
mediated phenomena are centrally responsible for malaria-related
deaths and that therapeutics and vaccines that interfere with
cytoadherence may reduce malaria mortality.
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